Provided by Tiger Trade Technology Pte. Ltd.

Celldex Therapeutics

29.07
-0.2300-0.78%
Volume:47.27K
Turnover:1.38M
Market Cap:2.28B
PE:-6.70
High:29.32
Open:29.04
Low:28.92
Close:29.30
52wk High:45.14
52wk Low:22.10
Shares:78.49M
Float Shares:73.02M
Volume Ratio:0.64
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3401
EPS(LYR):-3.9000
ROE:-43.88%
ROA:-27.62%
PB:3.19
PE(LYR):-7.45

Loading ...

Celldex Q2 FY26 Net Loss Widens to $73.5 Million; R&D Expenses Climb to $67.5 Million

Reuters
·
Aug 07

Celldex Therapeutics Q2 Revenue USD 22 Thousand

THOMSON REUTERS
·
Aug 07

Celldex Therapeutics (CLDX) After Phase 2 Trial Results As Valuation Questions Come Into Focus

Simply Wall St.
·
Aug 01

PharmaCyte Net Loss Widens to $19.42 Million in FY26; Revenue Remains no Revenue

Reuters
·
Jul 30

U.S. Research ROUNDUP-Boeing, Coca-Cola, PayPal

Reuters
·
Jul 29

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Celldex (CLDX)

TIPRANKS
·
Jul 25

U.S. Stocks on the Move-ge Vernova, Arrowhead Pharma

Reuters
·
Jul 22

Celldex Therapeutics Shares Down 2.6% After Scrapping Development of Skin Disease Drug

THOMSON REUTERS
·
Jul 22

Analysts Are Bullish on Top Healthcare Stocks: Vanda (VNDA), Celldex (CLDX)

TIPRANKS
·
Jul 22

Celldex price target lowered to $61 from $67 at Cantor Fitzgerald

TIPRANKS
·
Jul 22

Celldex Therapeutics is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jul 22

Wells Fargo Keeps Their Buy Rating on Celldex (CLDX)

TIPRANKS
·
Jul 22

Celldex Therapeutics Inc : Morgan Stanley Cuts Target Price to $40.00 from $44.00

THOMSON REUTERS
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), Bristol-Myers Squibb (BMY) and Peptidream (OtherPPTDF)

TIPRANKS
·
Jul 22

Celldex Therapeutics Inc : Leerink Partners Cuts Target Price to $70 from $78

THOMSON REUTERS
·
Jul 22

Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating

MT Newswires Live
·
Jul 22

U.s. Research Roundup-danaher, Gm, Msci

Reuters
·
Jul 22

Celldex Shares Fall After it Drops Skin Disease Drug Study

Reuters
·
Jul 22

Celldex to End Phase 2 Study for Skin-disease Treatment

Dow Jones
·
Jul 22

Celldex reports barzolvolimab study did not meet primary, secondary endpoints

TIPRANKS
·
Jul 22